Complications with new oral anticoagulants dabigatran and rivaroxaban in cutaneous surgery

Timothy W. Chang, Christopher J. Arpey, Christian Baum, Jerry D. Brewer, Phillip C. Hochwalt, Thomas L. Hocker, Randall K. Roenigk, Clark C. Otley

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND Anticoagulant medications to date are not associated with increased risk of severe lifethreatening complications during cutaneous surgery. Dabigatran and rivaroxaban are new orally administered anticoagulants that do not require laboratory monitoring and have no available specific antidotes, making perioperative management more complex. To the authors' knowledge, published data on the use of dabigatran or rivaroxaban in patients undergoing cutaneous surgery are limited. OBJECTIVE The authors sought to study perioperative complications associated with dabigatran and rivaroxaban during cutaneous surgery. MATERIALS AND METHODS Retrospective chart analysis was performed for all patients who underwent Mohs micrographic surgery or basic excision while taking dabigatran or rivaroxaban between January 1, 2010, and September 1, 2013, at Mayo Clinic, Rochester, MN. RESULTS Twenty-seven patients taking dabigatran underwent 41 cutaneous surgeries, with only 1 mild bleeding complication observed that was remedied with a pressure dressing. Four patients on rivaroxaban underwent 5 cutaneous surgeries without complication. CONCLUSION Because no patients on dabigatran or rivaroxaban experienced severe hemorrhagic complications during cutaneous surgery, a strategy of continuing these medically necessary medications during cutaneous surgery seems reasonable.

Original languageEnglish (US)
Pages (from-to)784-793
Number of pages10
JournalDermatologic Surgery
Volume41
Issue number7
DOIs
StatePublished - Jul 9 2015

Fingerprint

Dermatologic Surgical Procedures
Anticoagulants
Mohs Surgery
Antidotes
Bandages
Dabigatran
Rivaroxaban
Hemorrhage
Pressure

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Chang, T. W., Arpey, C. J., Baum, C., Brewer, J. D., Hochwalt, P. C., Hocker, T. L., ... Otley, C. C. (2015). Complications with new oral anticoagulants dabigatran and rivaroxaban in cutaneous surgery. Dermatologic Surgery, 41(7), 784-793. https://doi.org/10.1097/DSS.0000000000000392

Complications with new oral anticoagulants dabigatran and rivaroxaban in cutaneous surgery. / Chang, Timothy W.; Arpey, Christopher J.; Baum, Christian; Brewer, Jerry D.; Hochwalt, Phillip C.; Hocker, Thomas L.; Roenigk, Randall K.; Otley, Clark C.

In: Dermatologic Surgery, Vol. 41, No. 7, 09.07.2015, p. 784-793.

Research output: Contribution to journalArticle

Chang, TW, Arpey, CJ, Baum, C, Brewer, JD, Hochwalt, PC, Hocker, TL, Roenigk, RK & Otley, CC 2015, 'Complications with new oral anticoagulants dabigatran and rivaroxaban in cutaneous surgery', Dermatologic Surgery, vol. 41, no. 7, pp. 784-793. https://doi.org/10.1097/DSS.0000000000000392
Chang, Timothy W. ; Arpey, Christopher J. ; Baum, Christian ; Brewer, Jerry D. ; Hochwalt, Phillip C. ; Hocker, Thomas L. ; Roenigk, Randall K. ; Otley, Clark C. / Complications with new oral anticoagulants dabigatran and rivaroxaban in cutaneous surgery. In: Dermatologic Surgery. 2015 ; Vol. 41, No. 7. pp. 784-793.
@article{8c0bb1868d6245b28131daadbee6cf70,
title = "Complications with new oral anticoagulants dabigatran and rivaroxaban in cutaneous surgery",
abstract = "BACKGROUND Anticoagulant medications to date are not associated with increased risk of severe lifethreatening complications during cutaneous surgery. Dabigatran and rivaroxaban are new orally administered anticoagulants that do not require laboratory monitoring and have no available specific antidotes, making perioperative management more complex. To the authors' knowledge, published data on the use of dabigatran or rivaroxaban in patients undergoing cutaneous surgery are limited. OBJECTIVE The authors sought to study perioperative complications associated with dabigatran and rivaroxaban during cutaneous surgery. MATERIALS AND METHODS Retrospective chart analysis was performed for all patients who underwent Mohs micrographic surgery or basic excision while taking dabigatran or rivaroxaban between January 1, 2010, and September 1, 2013, at Mayo Clinic, Rochester, MN. RESULTS Twenty-seven patients taking dabigatran underwent 41 cutaneous surgeries, with only 1 mild bleeding complication observed that was remedied with a pressure dressing. Four patients on rivaroxaban underwent 5 cutaneous surgeries without complication. CONCLUSION Because no patients on dabigatran or rivaroxaban experienced severe hemorrhagic complications during cutaneous surgery, a strategy of continuing these medically necessary medications during cutaneous surgery seems reasonable.",
author = "Chang, {Timothy W.} and Arpey, {Christopher J.} and Christian Baum and Brewer, {Jerry D.} and Hochwalt, {Phillip C.} and Hocker, {Thomas L.} and Roenigk, {Randall K.} and Otley, {Clark C.}",
year = "2015",
month = "7",
day = "9",
doi = "10.1097/DSS.0000000000000392",
language = "English (US)",
volume = "41",
pages = "784--793",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Complications with new oral anticoagulants dabigatran and rivaroxaban in cutaneous surgery

AU - Chang, Timothy W.

AU - Arpey, Christopher J.

AU - Baum, Christian

AU - Brewer, Jerry D.

AU - Hochwalt, Phillip C.

AU - Hocker, Thomas L.

AU - Roenigk, Randall K.

AU - Otley, Clark C.

PY - 2015/7/9

Y1 - 2015/7/9

N2 - BACKGROUND Anticoagulant medications to date are not associated with increased risk of severe lifethreatening complications during cutaneous surgery. Dabigatran and rivaroxaban are new orally administered anticoagulants that do not require laboratory monitoring and have no available specific antidotes, making perioperative management more complex. To the authors' knowledge, published data on the use of dabigatran or rivaroxaban in patients undergoing cutaneous surgery are limited. OBJECTIVE The authors sought to study perioperative complications associated with dabigatran and rivaroxaban during cutaneous surgery. MATERIALS AND METHODS Retrospective chart analysis was performed for all patients who underwent Mohs micrographic surgery or basic excision while taking dabigatran or rivaroxaban between January 1, 2010, and September 1, 2013, at Mayo Clinic, Rochester, MN. RESULTS Twenty-seven patients taking dabigatran underwent 41 cutaneous surgeries, with only 1 mild bleeding complication observed that was remedied with a pressure dressing. Four patients on rivaroxaban underwent 5 cutaneous surgeries without complication. CONCLUSION Because no patients on dabigatran or rivaroxaban experienced severe hemorrhagic complications during cutaneous surgery, a strategy of continuing these medically necessary medications during cutaneous surgery seems reasonable.

AB - BACKGROUND Anticoagulant medications to date are not associated with increased risk of severe lifethreatening complications during cutaneous surgery. Dabigatran and rivaroxaban are new orally administered anticoagulants that do not require laboratory monitoring and have no available specific antidotes, making perioperative management more complex. To the authors' knowledge, published data on the use of dabigatran or rivaroxaban in patients undergoing cutaneous surgery are limited. OBJECTIVE The authors sought to study perioperative complications associated with dabigatran and rivaroxaban during cutaneous surgery. MATERIALS AND METHODS Retrospective chart analysis was performed for all patients who underwent Mohs micrographic surgery or basic excision while taking dabigatran or rivaroxaban between January 1, 2010, and September 1, 2013, at Mayo Clinic, Rochester, MN. RESULTS Twenty-seven patients taking dabigatran underwent 41 cutaneous surgeries, with only 1 mild bleeding complication observed that was remedied with a pressure dressing. Four patients on rivaroxaban underwent 5 cutaneous surgeries without complication. CONCLUSION Because no patients on dabigatran or rivaroxaban experienced severe hemorrhagic complications during cutaneous surgery, a strategy of continuing these medically necessary medications during cutaneous surgery seems reasonable.

UR - http://www.scopus.com/inward/record.url?scp=84936889874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936889874&partnerID=8YFLogxK

U2 - 10.1097/DSS.0000000000000392

DO - 10.1097/DSS.0000000000000392

M3 - Article

C2 - 26057410

AN - SCOPUS:84936889874

VL - 41

SP - 784

EP - 793

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 7

ER -